Hemorrhagic Diathesis With Prolonged Coagulation Time Associated With a Circulating Anticoagulant

Product type and other environmental risk factors for inhibitor development in severe hemophilia A

“…A circulating inhibitor, called “anticoagulant,” was identified for the first time in the 1940s in a patient affected with hemophilia . Three hours after the blood transfusions, the patient began to bleed continuously and the coagulation time remained markedly prolonged . Later, this inhibitor was shown to be a γ‐globulin and to appear only after repeated transfusions of whole blood .…”

Le rôle des inhibiteurs faibles du facteur VIII

“…La littérature des inhibiteurs du facteur VIII est devenue considé rable [17,26] depuis que L o z n e r et al [16] en publièrent le premier cas spontané et que M u n r o et J o n es [19] les trouvèrent chez l'hémo phile classique A. Aujourd'hui, la plupart des auteurs les considèrent comme des anticorps (29,14), 7 S y-globulines [1,28] associés à des 19 S y-M globulines [30], Ig globulines à chaînes légères, semblables aux autoanticorps froids des anémies hémolytiques [27]. Cependant tous ne sont peut-être pas des y-globulines [24,25].…”

Studies on the Initiation of Blood Coagulation. Ii. An Anticoagulant Inhibiting the Activation of a Plasma Thromboplastic Factor 1

“…Further evidence in support of the existence of a potentially thromboplastic plasma factor has been provided by the study of certain patients whose plasma contained a circulating anticoagulant (12,16,(19)(20)(21)(22)(23)(24)(25)(26). Such an anticoagulant, present in the plasma of the patient described in this report, did not inhibit the action of thrombin, prothrombin, accelerator globulin, or a variety of thromboplastic substances including human and rabbit brain, platelet suspensions and Russell viper venom.…”